Who are Relugolix + Estradiol + Norethindrone Acetate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/relugolix-estradiol-norethindrone-acetate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Relugolix + Estradiol + Norethindrone Acetate — Competitive Intelligence Brief

Relugolix + Estradiol + Norethindrone Acetate (Relugolix + Estradiol + Norethindrone Acetate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH antagonist combination with hormone replacement therapy. Area: Gynecology / Endometriosis.

marketed GnRH antagonist combination with hormone replacement therapy GnRH receptor (relugolix component) Gynecology / Endometriosis Small molecule Live · refreshed every 30 min

Target snapshot

Relugolix + Estradiol + Norethindrone Acetate (Relugolix + Estradiol + Norethindrone Acetate) — Sumitomo Pharma Switzerland GmbH. Relugolix suppresses luteinizing hormone and follicle-stimulating hormone by antagonizing GnRH receptors, while estradiol and norethindrone acetate provide hormone replacement to manage menopausal symptoms in women with endometriosis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Relugolix + Estradiol + Norethindrone Acetate TARGET	Relugolix + Estradiol + Norethindrone Acetate	Sumitomo Pharma Switzerland GmbH	marketed	GnRH antagonist combination with hormone replacement therapy	GnRH receptor (relugolix component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GnRH antagonist combination with hormone replacement therapy class)

Sumitomo Pharma Switzerland GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Relugolix + Estradiol + Norethindrone Acetate — Competitive Intelligence Brief. https://druglandscape.com/ci/relugolix-estradiol-norethindrone-acetate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab